Form 4: Black Diamond Therapeutics Director Kapil Dhingra Granted Significant Stock Options

Black Diamond Therapeutics, Inc. Director Kapil Dhingra was granted 30,550 stock options with an exercise price of $2.43, vesting fully by June 12, 2026, or the next annual meeting.

Summary

• Kapil Dhingra, a Director at Black Diamond Therapeutics, Inc. (BDTX), acquired 30,550 stock options.
• The transaction date for this acquisition was June 12, 2025.
• Each option has an exercise price of $2.43.
• The options are set to expire on June 11, 2035.
• The 30,550 shares underlying these options are common stock.
• The options will vest and become exercisable in full upon the earlier of June 12, 2026, or the Issuer's next annual meeting of stockholders, contingent on Mr. Dhingra's continued service.

Sentiment

Score: 6

Explanation: The document reports a standard compensation event (stock option grant) for a director, which is generally viewed as a neutral to slightly positive development as it aligns management interests with shareholders. There are no negative implications or significant risks disclosed.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• The exercise price of $2.43 provides a clear benchmark for future stock performance relative to the grant.

Future Outlook

The stock options are subject to future vesting, which will occur in full upon the earlier of June 12, 2026, or the Issuer's next annual meeting of stockholders, provided the reporting person continues their service.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of long-term incentive compensation to align leadership interests with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard component of executive and board compensation packages across the biotechnology sector, aiming to incentivize long-term performance and retention.
• The vesting schedule, tied to continued service and a specific future date or corporate event (annual meeting), is typical for such equity grants in publicly traded companies.

Corporate Governance

Related Party Transactions

• The grant of stock options to Kapil Dhingra, a Director of Black Diamond Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options will vest and become exercisable upon the earlier of June 12, 2026, or the Issuer's next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Black Diamond Therapeutics, BDTX, Kapil Dhingra, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biotechnology